Clinical trials: COPD Chronic Obstructive Pulmonary Disease
Pulmonary Disease, Chronic Obstructive
A Single Centre Randomized Study Evaluating The Safety And Tolerability Of GSK233705 In Healthy Volunteers.
This study will investigate the safety and tolerability of inhaled doses of GSK233705 with a new formulation.
- Trial name
- NCT00453687
- Testing
- GSK233705
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease (COPD)
Validation of Structured Light Plethysmography - Health and Disease
Validation of Structured Light Plethysmography (SLP) in patients with conditions such as Chronic Obstructive Pulmonary Disease (COPD) that effect breathing and in healthy participants.
- Trial name
- SLP-RespDis (NCT02626468)
- Where
- United Kingdom
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Pneumacare Ltd
Healthy
The Bioavailability of a Spray Dried Dispersion Solid Dose Formulation of PF-06260414 Relative to a Suspension Formulation
The current study will investigate the relative bioavailability of a spray dried dispersion solid dose formulation of PF 06260414 administered as a single oral dose of 30 mg of PF 06260414 relative to a single oral dose of 30 mg…
- Trial name
- NCT02393807
- Testing
- PF 06260414 solid dose formulation, PF-06260414 nanosuspension
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pfizer
Pulmonary Emphysema, Chronic Obstructive Pulmonary Disease
US Biologic Lung Volume Reduction (BLVR) Phase 2 Emphysema Study
The purpose of this study it to evaluate the efficacy and safety of the 20 mL BLVR System in patients with advanced upper lobe predominant emphysema.
- Trial name
- NCT00515164
- Testing
- Biologic Lung Volume Reduction (BLVR) - 20 mL Hydrogel
- Where
- 8 sites in United States
- Volunteers
- 22 people
- Sponsor
- Aeris Therapeutics
COPD
Evaluation of Safety and Effectiveness of TLD Radiofrequency Ablation in the Treatment of COPD
The objective of this trial is to evaluate the safety and effectiveness of Targeted Lung Denervation (TLD) for COPD patients using the lung denervation radiofrequency ablation device.
- Trial name
- NCT05799664
- Testing
- TLD, Standard of care
- Where
- China
- Volunteers
- 189 people
- Sponsor
- Hangzhou Broncus Medical Co., Ltd.
Chronic Obstructive Pulmonary Disease
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
This is a parallel, Phase 2b/Phase 3, 3-arm study to investigate the efficacy, safety, and tolerability of subcutaneous (SC) treatment with lunsekimig compared with placebo in adult participants (aged 40 to 80 years, inclusive)…
- Trial name
- PERSEPHONE (NCT07190209)
- Testing
- Lunsekimig
- Where
- 314 sites in United States, Argentina and 23 more
- Volunteers
- 942 people
- Sponsor
- Sanofi
Chronic Obstructive Pulmonary Disease
Safety, Tolerability, and Pharmacokinetics of Andecaliximab in Adults With Chronic Obstructive Pulmonary Disease (COPD)
The primary objective of the study is to assess the safety and tolerability of multiple infusions of andecaliximab (formerly GS-5745) in participants with chronic obstructive pulmonary disease (COPD) as assessed by adverse events…
- Trial name
- NCT02077465
- Testing
- Andecaliximab
- Where
- 5 sites in United States
- Volunteers
- 11 people
- Sponsor
- Gilead Sciences
Pulmonary Disease, Chronic Obstructive
A 24 Week Efficacy Study of Inhaled Umeclidinium (UMEC) in Patients of Chronic Obstructive Pulmonary Disease (COPD) Using a Novel Dry Powder Inhaler (NDPI)
Studies to date provides substantial evidence for the effectiveness for UMEC 62.5 microgram (mcg) as a long term maintenance therapy for the treatment of COPD; this study further evaluates the efficacy and safety of UMEC 62.5 mcg…
- Trial name
- NCT02184611
- Testing
- Umeclidinium bromide
- Where
- 26 sites in China, South Korea
- Volunteers
- 308 people
- Sponsor
- GlaxoSmithKline
Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)
Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- NCT03118765
- Testing
- GSP304 (tiotropium bromide) Inhalation Solution, Spiriva® Respimat® inhalation spray
- Where
- 25 sites in United States
- Volunteers
- 155 people
- Sponsor
- Glenmark Specialty S.A.
Pulmonary Disease, Chronic Obstructive
Drug Use Survey of RESPIMAT in Patients With COPD
To investigate safety and effectiveness information on the use of Tiotropium Respimat for long time of period in daily practical clinical circumstances, and to obtain proper drug use information.
- Trial name
- NCT01145053
- Volunteers
- 361 people
- Sponsor
- Boehringer Ingelheim
COPD, Asthma
AirSonea Wheeze Detection Study
The purpose of this study is to determine if the AirSonea device provides an objective assessment of breath sounds for the presence of wheeze in both medical and home environments.
- Trial name
- NCT01927172
- Testing
- AirSonea
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- iSonea
COPD, Chronic Obstructive Pulmonary Disease
Trial to Assess the Anti-inflammatory Effects of Roflumilast in Chronic Obstructive Pulmonary Disease
The objective of the Biopsy trial is to investigate the effect of roflumilast 500 µg tablets once daily versus placebo on inflammation parameters in bronchial biopsy tissue specimen and additional in sputum and blood serum.
- Trial name
- NCT01509677
- Testing
- Roflumilast
- Where
- 20 sites in Denmark, Germany and 3 more
- Volunteers
- 158 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
Effect of Roflumilast on Lung Function in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Salmeterol: The EOS Study (BY217/M2-127)
The aim of the study is to compare the efficacy of roflumilast on pulmonary function and symptomatic parameters in patients with chronic obstructive pulmonary disease (COPD) during concomitant administration of salmeterol.
- Trial name
- EOS (NCT00313209)
- Testing
- Roflumilast
- Where
- 134 sites in Austria, Belgium and 8 more
- Volunteers
- 933 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
A Study to Evaluate the Safety, Efficacy and Changes in Induced Sputum and Blood Biomarkers Following Daily Repeat Doses of Inhaled GSK2269557 in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Acute Exacerbation
The purpose of this study is to evaluate specific alterations in immune cell mechanisms related to neutrophil function as detected by PI3Kdelta-dependent changes in messenger ribonucleic acid (mRNA) extracted from induced sputum…
- Trial name
- NCT02522299
- Testing
- GSK2269557, DISKUS, ELLIPTA
- Where
- 6 sites in Canada, Denmark
- Volunteers
- 44 people
- Sponsor
- GlaxoSmithKline
COPD, Healthy Volunteers
A Study to Investigate the Safety and Tolerability of a New Inhaled Formulation of RV568 in Healthy Volunteers
RV568 is being developed as a possible treatment of smoking related lung disease (also known as Chronic Obstructive Pulmonary Disease - COPD).
- Trial name
- NCT01661244
- Testing
- RV568 single dose, RV568 repeat dose
- Where
- United Kingdom
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Respivert Ltd
Chronic Obstructive Pulmonary Disease
Assessment of the Safety and Ability of a Once-a-day Dose of an Orally Inhaled Medicine [ie, Glycopyrrolate Inhalation Solution = GIS] to Improve Airflow in the Lungs When Delivered With an Electronic eFlow Nebulizer System in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The study assessed the safety and ability of several doses of an orally inhaled medicine [ie, Glycopyrrolate Inhalation Solution = GIS] to improve airflow in the lungs when delivered with an electronic eFlow nebulizer system in…
- Trial name
- NCT02951312
- Testing
- Glycopyrrolate Inhalation Solution 25mg, Glycopyrrolate Inhalation Solution 75mg, Glycopyrrolate Inhalation Solution 200mg
- Volunteers
- 12 people
- Sponsor
- Sunovion Respiratory Development Inc.
COPD
Observational Multicenter Non-interventional Study on COPD Patients Treatment Strategies at the Time of Hospital Discharge and Within 12 Months of Follow-up on an Outpatient Primary Care Basement
The study is an observational multicenter descriptive study. It is planned to enroll approximately 1250 subjects with severe and very severe COPD hospitalized for the reason of COPD exacerbation into departments of pulmonology or…
- Trial name
- CLOUD (NCT02346292)
- Where
- 30 sites in Russia
- Volunteers
- 1,250 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Outcomes and Costs Associated With Initiating Maintenance Treatment With Fluticasone Propionate 250mcg/Salmeterol Xinafoate 50mcg Combination (FSC) Versus Anticholinergics Including Tiotropium (TIO) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
To evaluate COPD-related clinical outcomes and total healthcare utilization in commercially insured (at least 40 years with a subanalysis of those aged 65 years and older) COPD population associated with the use of…
- Trial name
- NCT01331694
- Testing
- fluticasone/salmeterol combination (FSC) 250/50mcg, tiotropium, ipratropium bromide alone or in fixed dose combination with albuterol
- Volunteers
- 76,130 people
- Sponsor
- GlaxoSmithKline
COPD
Bronchodilator Effect of RPL554 Administered in Addition to Tiotropium/Olodaterol in Patients With COPD
The study investigates the effect of 3 days of twice daily treatment of two different doses of RPL554 (a phosphodiesterase [PDE]3/4 inhibitor) or placebo, each administered in addition to once daily tiotropium/olodaterol…
- Trial name
- NCT03673670
- Testing
- RPL554 Suspension, Tiotropium/olodaterol (Respimat)
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 79 people
- Sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Pulmonary Disease, Chronic Obstructive
Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary Disease
The primary objective of this study is to evaluate long-term safety and patient acceptability of COMBIVENT RESPIMAT Inhalation Spray as compared to the COMBIVENT Inhalation Aerosol Chlorofluorocarbon-Metered Dose Inhaler…
- Trial name
- NCT01019694
- Testing
- Combivent CFC-MDI, Combivent Respimat 20/100 mcg, Atrovent HFA 42 mcg + Albuterol HFA 200 mcg
- Where
- 55 sites in United States
- Volunteers
- 470 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.